MRKMerck & Co.

$145.57+83% 1Y

$145.57

$75.8352 weeks$156.44

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though at the top of its own P/E range.

1 to watch, 1 neutral, 1 without data

What the price assumes~+4% a yearderived · Jun 30, 2026

Priced for ~4% a year FCF growth. Roughly in line with its three-year revenue growth of 5% a year.

Vs its own P/E rangedearest in 40 quartersderived

Expensive vs its own history: P/E 115.5 vs a 22.4 median over 40 quarters (+416% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 4% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Merck & Co. trades at 116× earnings against 26.2× for the median Drug Manufacturers - General name, more expensive than its own group.

116

Trailing P/E · Drug Manufacturers - General median 26.2 · 4.40× the median: the market pays up for this one

Price / sales: 4.22
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 5.7%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: +3.9%
Growth the price implies · The price pays for +3.9% free cash flow growth a year for a decade; the business has delivered +14% a year over the last three.